Xbrane Biopharma AB (publ)
XBRANE
Rank in Stocks
#27382
Xbrane Biopharma AB (publ) is a biotechnology firm, founded in 2008 and based... Xbrane Biopharma AB (publ) is a biotechnology firm, founded in 2008 and based in Solna, Sweden, that specializes in the creation, manufacturing, and distribution of biosimilar medications. The company's development pipeline includes Xlucane, a ranibizumab biosimilar presently undergoing pivotal Phase III clinical trials. This therapeutic candidate is being evaluated for the treatment of several serious eye conditions, including wet age-related macular degeneration, diabetic macular edema, diabetic retinopathy, and retinal vein occlusion. In its earlier, preclinical stages, Xbrane is progressing a range of biosimilars: Xcimzane: Targeting autoimmune diseases such as rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, psoriasis, and Crohn's disease. Xoncane: Designed for acute lymphocytic leukemia. Spherotide: Intended for prostate cancer, breast cancer, endometriosis, and uterine myoma. Xdivane: Developed for various cancers, including melanoma, lung cancer, head and throat cancer, bladder cancer, urinary tract cancer, and renal cell carcinoma. Moreover, Xbrane has established a strategic partnership with STADA Arzneimittel AG. This collaboration aims to explore and potentially pursue joint development and commercialization opportunities for its preclinical biosimilar candidates, Xcimzane and Xdivane.
Share Price
$1.25
Last synced: 2026-11-09
Market Cap
$15.22M
Change (1 day)
-2.66%
Change (1 year)
16.61%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Xbrane Biopharma AB (publ) (XBRANE)
Category
Healthcare
Operating Margin for Xbrane Biopharma AB (publ) (XBRANE)
Operating Margin as of November 2026 TTM: -45.28%
According to Xbrane Biopharma AB (publ)'s latest financial reports, its current operating margin (TTM) is -45.28%. At the end of 2025 the company had an operating margin of -47.35%.
Operating Margin history for Xbrane Biopharma AB (publ) from 2012 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -45.28% | -4.37% |
| 2025 | -47.35% | -56.83% |
| 2024 | -109.67% | -15.66% |
| 2023 | -130.03% | -54.93% |
| 2022 | -288.48% | -81.56% |
| 2021 | -1,564.18% | -52.42% |
| 2020 | -3,287.67% | -88.02% |
| 2019 | -27,436.67% | 271,281.50% |
| 2018 | -10.11% | -95.30% |
| 2017 | -215.29% | -83.86% |
| 2016 | -1,334.14% | -49.93% |
| 2015 | -2,664.73% | 96.30% |
| 2014 | -1,357.47% | 22.08% |
| 2013 | -1,111.92% | 1,223.40% |
| 2012 | -84.02% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -100.85% |
US
|
|
| -149.01% | -96.71% |
US
|
|
| 25.57% | -100.56% |
AU
|
|
| 31.23% | -100.69% |
BE
|
|
| 29.35% | -100.65% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Xbrane Biopharma AB (publ)'s operating margin
What is Xbrane Biopharma AB (publ)'s operating margin?
Xbrane Biopharma AB (publ)'s operating margin is -45.28%, as of Nov 2026.
What was Xbrane Biopharma AB (publ)'s operating margin in 2025?
In 2025, Xbrane Biopharma AB (publ)'s operating margin was -47.35%, compared with -109.67% in 2024.
How has Xbrane Biopharma AB (publ)'s operating margin changed since 2020?
From 2020 to 2025, Xbrane Biopharma AB (publ)'s operating margin was highest in 2025 (-47.35%) and lowest in 2020 (-3,287.67%).
How does Xbrane Biopharma AB (publ)'s operating margin compare with similar companies?
Xbrane Biopharma AB (publ)'s operating margin (-45.28%) is higher than that of 1 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.